Market Size of Next-Generation Immunology Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Next-Generation Immunology Drugs Market Analysis
The Next-Generation Immunology Drugs Market is expected to register a CAGR of 6.1% over the forecast period.
The COVID-19 pandemic had a significant impact on the market studied. During the pandemic, immunology research was increased to understand the effects of COVID-19 on immunity and cope with the severe effects of the same. For instance, the University of Oxford Immunology Network conducted research on COVID-19 in early 2021 that was focused on humoral immunity, deep phenotyping, the inflammatory response, and cell immunity. Additionally, research in the area of immunology drugs for COVID-19 increased during the pandemic. For instance, JAK and BTK inhibitors were immunomodulatory drugs that were evaluated to treat COVID-19. GM-CSF Inhibitors. The rising research on immunology drugs to combat the COVID-19 disease fueled the market's growth. However, currently, the market has reached its pre-pandemic nature and is expected to witness significant growth over the forecast period.
Some of the key factors propelling market growth include the rising burden of chronic diseases, increasing research in the area of next-generation drugs, and an increased focus on targeted therapies for certain diseases.
The market for next-generation immunology drugs is expected to witness a healthy growth due to the rising prevalence of chronic diseases like asthma, allergic conditions, cancer, and multiple sclerosis. For instance, a January 2023 report from the American Cancer Society indicated that by the year 2040, there will be more than 16.3 million cancer-related deaths and over 27.5 million new cases worldwide due to population growth and aging. The burden will probably increase in the future because risk factors including smoking, eating poorly, and not exercising are becoming more prevalent in economically developing countries. With growing chronic diseases, pharmaceutical companies are focusing more on R&D and developing novel drugs, which is contributing to market growth.
Furthermore, the key activities undertaken by the various companies are supporting market growth. For instance, in November 2022, Human Immunology Biosciences announced that it had raised USD 120 million to develop targeted treatments for autoimmune and allergic diseases. The company developed two drug candidates, called felzartamab and HIB210, that were licensed from the German biotechnology company MorphoSys. Both are in clinical trials, with the former in Phase 2 testing for two rare kidney diseases and the latter in Phase 1. Hence, owing to the increasing focus of companies on developing such novel drugs, it is believed that the market studied is likely to witness strong growth. However, the high cost of next-generation drugs and stringent regulatory policies are some of the factors that are expected to restrain market growth.
Next-Generation Immunology Drugs Industry Segmentation
As per the scope of this report, next-generation immunology drugs refers to a new class of medications that are designed to modulate the immune system in a more targeted and precise way compared to traditional immunomodulatory drugs. The Next-Generation Immunology Drugs Market is segmented by Drug Type (Small Molecules, Antibodies, Cell-Based Therapies, Others), Therapeutic Area (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Drug Class | |
| Small Molecules | |
| Antibodies | |
| Cell Based Therapies | |
| Other Drug Classes |
| By Therapeutic Area | |
| Cancer | |
| Autoimmune Diseases | |
| Infectious Diseases | |
| Inflammatory Diseases | |
| Other Therapeutic Areas |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Next-Generation Immunology Drugs Market Size Summary
The next-generation immunology drugs market is poised for substantial growth, driven by the increasing prevalence of chronic diseases such as cancer, asthma, and multiple sclerosis. The market's expansion is supported by a surge in research and development activities focused on novel therapies and targeted treatments. The COVID-19 pandemic initially spurred heightened research in immunology, leading to advancements in drug development, although the market has since stabilized to its pre-pandemic state. Key players in the industry are actively engaged in developing and launching new drugs, which is expected to further propel market growth. However, challenges such as the high cost of these drugs and stringent regulatory policies may pose obstacles to market expansion.
North America, particularly the United States, is a significant hub for the next-generation immunology drugs market, benefiting from a robust pharmaceutical research and development sector and the presence of major industry players. The rising global cancer burden, especially in countries like the United States, Canada, the United Kingdom, and India, is creating lucrative opportunities for market participants. The introduction of new immunotherapy drugs and the focus on innovative treatments are key factors driving market dynamics. Despite the competitive landscape, with several major players dominating the market, ongoing product launches and strategic collaborations are expected to enhance market share and foster further growth in the coming years.
Next-Generation Immunology Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Burden of Chronic Diseases
-
1.2.2 Increasing Research in the Area of Next Generation Drugs
-
1.2.3 Increasing Focus on Targeted Therapies
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Next Generation Drugs
-
1.3.2 Stringent Regulatory Policies
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Drug Class
-
2.1.1 Small Molecules
-
2.1.2 Antibodies
-
2.1.3 Cell Based Therapies
-
2.1.4 Other Drug Classes
-
-
2.2 By Therapeutic Area
-
2.2.1 Cancer
-
2.2.2 Autoimmune Diseases
-
2.2.3 Infectious Diseases
-
2.2.4 Inflammatory Diseases
-
2.2.5 Other Therapeutic Areas
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Next-Generation Immunology Drugs Market Size FAQs
What is the current Next-Generation Immunology Drugs Market size?
The Next-Generation Immunology Drugs Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)
Who are the key players in Next-Generation Immunology Drugs Market?
AbbVie, Novartis AG, GSK plc, Pfizer Inc. and Bristol-Myers Squibb Company are the major companies operating in the Next-Generation Immunology Drugs Market.
